Bernardo Haddock Lobo Goulart (@lobo_goulart) 's Twitter Profile
Bernardo Haddock Lobo Goulart

@lobo_goulart

Rough on the outside, a softie at the core; love my girls; data obsessive; Thoracic oncologist; outcomes researcher; @martialarts; @skiing. Views are own.

ID: 1237789786590474240

calendar_today11-03-2020 17:19:17

258 Tweet

164 Followers

117 Following

Katie Campbell (@campkatiee) 's Twitter Profile Photo

We need more smaller trials to evaluate the other checkpoints and understand whether they’re induced within and across cancer types. This is how we can understand when each combination should be used. Padmanee (Pam) Sharma, MD, PhD Jim Allison PhD AACR #AACR24

We need more smaller trials to evaluate the other checkpoints and understand whether they’re induced within and across cancer types. This is how we can understand when each combination should be used. <a href="/PamSharmaMDPhD/">Padmanee (Pam) Sharma, MD, PhD</a> <a href="/JimAllisonPhD/">Jim Allison PhD</a> <a href="/AACR/">AACR</a> #AACR24
AACR (@aacr) 's Twitter Profile Photo

The Future of Registrational Trials with Multiple Arms: Bernardo Haddock Lobo Goulart will moderate this session at the FDA Oncology-AACR workshop on Trial Designs for Treatment Regimens with Multiple Phases (May 9). Learn more: bit.ly/3weWwmx #AACRSciencePolicy

The Future of Registrational Trials with Multiple Arms: 
<a href="/lobo_goulart/">Bernardo Haddock Lobo Goulart</a> will moderate this session at the <a href="/FDAOncology/">FDA Oncology</a>-AACR workshop on Trial Designs for Treatment Regimens with Multiple Phases (May 9). Learn more: 
bit.ly/3weWwmx
#AACRSciencePolicy
AACR (@aacr) 's Twitter Profile Photo

.U.S. FDA's Bernardo Hoddock Lobo Goulart moderated a session on the Future of Registrational Trials With Multiple Arms. The session starts with a presentation by Minghua Shan of Bayer Pharmaceuticals. @Lobo_Goulart #AACRSciencePolicy

.<a href="/US_FDA/">U.S. FDA</a>'s Bernardo Hoddock Lobo Goulart moderated a session on the Future of Registrational Trials With Multiple Arms. The session starts with a presentation by Minghua Shan of Bayer Pharmaceuticals. @Lobo_Goulart #AACRSciencePolicy
Bernardo Haddock Lobo Goulart (@lobo_goulart) 's Twitter Profile Photo

Big call out for patient-centric trials of perioperative therapies today 👇 FDA-AACR Workshop: How Much is Enough? Trial Designs for Treatment Regimens with Multiple Phases - American Association for Cancer Research (AACR) aacr.org/professionals/…

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

Spread the word! National Black Family Cancer Awareness Week is approaching in June. Let's unite to raise awareness, reduce disparities, and eventually lower the cancer mortality rate within our community. Together, we can make a difference. #BlackFamCan youtu.be/7htK_8u3QqA?si…

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

Check out the state of immunotherapy in resectable NSCLC: This ASCO Ed Book article includes views from academia & FDA. Good warmup for #ASCO24 Education Session “Integrating Immunotherapy into Early-Stage Lung Cancer" on June 2. 🧵 1/2 ascopubs.org/doi/10.1200/ED… #OCEPublications

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

2/2 → Ongoing trials of immunotherapy and RT for early stage NSCLC. → Clinical implications of recent advances in immunotherapy for resectable NSCLC. → Current trial designs assessing immunotherapy in resectable NSCLC: challenges, opportunities. Bernardo Haddock Lobo Goulart #ASCO24

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

Attending #ASCO24? FDA Oncology experts will be speaking ASCO Annual Meeting May 31-June 4 in Chicago. Add these talks to your calendar! fda.gov/about-fda/onco… #OCETalks

Bernardo Haddock Lobo Goulart (@lobo_goulart) 's Twitter Profile Photo

Look forward to discussing immunotherapy & trial designs for resectable NSCLC at #ASCO24 Ed session: Integrating Immunotherapy Into Early-Stage Lung Cancer. Join Rafal Dziadziuszko Jamie Chaft and Bernardo Haddock Lobo Goulart to review progress & challenges in this hot topic!

IASLC (@iaslc) 's Twitter Profile Photo

New commentary in #ILCN: Dr. Ke-Neng Chen highlights the importance of avoiding unnecessary treatments and using a multidisciplinary approach in the treatment of NSCLC. bit.ly/4aAgruj #LCSM

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

FDA Oncology Center's Dr. Luckson Mathieu will be speaking at Mass General Cancer Center 2024 #CancerEquityColloquium June 14-15. This hybrid event will address the diverse issues that underlie #cancerinequities. tinyurl.com/mryjj68b #OCETalks

FDA Oncology Center's Dr. Luckson Mathieu will be speaking at <a href="/MGHCancerCenter/">Mass General Cancer Center</a> 2024 #CancerEquityColloquium June 14-15. This hybrid event will address the diverse issues that underlie #cancerinequities. tinyurl.com/mryjj68b
#OCETalks
Jill Feldman (@jillfeldman4) 's Twitter Profile Photo

Just thinking...I strongly advocate changing the dose selection process to a minimal effective dose (balance efficacy with QOL), but I also think WE NEED A SHIFT IN the AE GRADING SYSTEM to include impact, not just safety. PRO's are invaluable for understanding the patient

Bernardo Haddock Lobo Goulart (@lobo_goulart) 's Twitter Profile Photo

Don’t fly with United Airlines. They cancelled 2 flights in a row - same day for the same destination - The second cancellation was after a 3.5 hour delay, with all passengers on board. “Exceeded FA time” That’s why Delta is leading this industry in the US.

Bernardo Haddock Lobo Goulart (@lobo_goulart) 's Twitter Profile Photo

Another option for patients with NSCLC and sensitizing EGFR mutations FDA Oncology Keep an eye on DVTs/PEs (36%) and don’t forget the recs for prophylactic anticoagulantion!

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

FDA approves lazertinib in combination with amivantamab-vmjw for locally advanced or metastatic non-small lung cancer with specific EGFR mutations. fda.gov/drugs/resource… #OCENewsBurst #lcsm

Wolf of X (@tradingmaxisl) 's Twitter Profile Photo

Ever wondered what everyday life was like for people living 50, 100, or more years ago..? A rare thread 1. That’s A Genuinely Happy Looking Family, USA, 1959

Ever wondered what everyday life was like for people living 50, 100, or more years ago..?

A rare thread 

1. That’s A Genuinely Happy Looking Family, USA, 1959